Émilie Laude, Henri Azaïs, Mehdi Ben Sassi, Anne-Sophie Bats, Valérie Taly, Pierre Laurent-Puig
{"title":"Clinical value of circulating tumor DNA for patients with epithelial ovarian cancer.","authors":"Émilie Laude, Henri Azaïs, Mehdi Ben Sassi, Anne-Sophie Bats, Valérie Taly, Pierre Laurent-Puig","doi":"10.1016/j.ijgc.2025.101925","DOIUrl":"10.1016/j.ijgc.2025.101925","url":null,"abstract":"<p><p>Despite progress in recent years, epithelial ovarian cancer remains a pathology with a poor prognosis, primarily because of late and invasive diagnosis. Conventional follow-up relies on imaging, CA125, and predictive tools such as KELIM-CA125 and the chemotherapy response score. However, these methods are non-specific and result in delays before obtaining results. Recently, many research teams have focused on liquid biopsies, which provide direct access to tumor material in biological fluids. This review examines the clinical potential of circulating tumor DNA (ctDNA) in epithelial ovarian cancer. A systematic search of the PubMed database was conducted. Inclusion criteria were studies published in English, original research articles, reviews, or meta-analyses focused on ctDNA and ovarian cancer. Exclusion criteria included non-peer-reviewed sources, articles with insufficient data, and studies not directly related to the topic. In epithelial ovarian cancer, ctDNA allows quantitative evaluation of tumor burden and qualitative analysis by detecting specific tumor DNA variations, such as epigenetic modifications or genetic mutations. Furthermore, its half-life is less than 2 hours, enabling dynamic monitoring of tumor evolution. This capability could facilitate earlier diagnosis, better screening, and more effective therapeutic follow-up. The qualitative approach also has the potential to predict chemoresistance. Technologies used to detect ctDNA in blood include quantitative polymerase chain reaction, digital polymerase chain reaction, and next-generation sequencing, which allow quantification and identification of DNA molecule modifications. CtDNA is a promising biomarker for epithelial ovarian cancer and could address several challenges in its management. However, further research is needed to establish its role in routine clinical practice, particularly, to identify a detection method that is highly sensitive, specific, and generalizable to a wide patient population.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101925"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Giuseppe Cucinella, Gabriella Schivardi, Xun Clare Zhou, Mariam M AlHilli, Sumer Wallace, Allan Covens, Christoph Wohlmuth, Glauco Baiocchi, Nedim Tokgozoglu, Francesco Raspagliesi, Alessandro Buda, Vanna Zanagnolo, Ignacio Zapardiel, Nisha Jagasia, Robert Giuntoli, Ariel Glickman, Michele Peiretti, Maximillian Lanner, Enrique Chacon, Julian Di Guilmi, Augusto Pereira, Enora Laas, Ami Fishman, Caroline C Nitschmann, Katherine Kurnit, Kristen Moriarty, Amy Joehlin-Price, Brittany Lees, Louise De Brot, Cagatay Taskiran, Giorgio Bogani, Fabio Landoni, Luis Chiva, Tommaso Grassi, Tommaso Bianchi, Francesco Multinu, Luigi Antonio De Vitis, Alicia Hernandez-Gutierrez, Spyridon Mastroyannis, Khaled Ghoniem, Emilia Palmieri, Vito Chiantera, Shahi Maryam, Angela J Fought, Michaela E McGree, Andrea Mariani, Gretchen Glaser
{"title":"Prognostic value of isolated tumor cells in sentinel lymph nodes in intermediate-risk endometrial cancer: results from an international, multi-institutional study.","authors":"Giuseppe Cucinella, Gabriella Schivardi, Xun Clare Zhou, Mariam M AlHilli, Sumer Wallace, Allan Covens, Christoph Wohlmuth, Glauco Baiocchi, Nedim Tokgozoglu, Francesco Raspagliesi, Alessandro Buda, Vanna Zanagnolo, Ignacio Zapardiel, Nisha Jagasia, Robert Giuntoli, Ariel Glickman, Michele Peiretti, Maximillian Lanner, Enrique Chacon, Julian Di Guilmi, Augusto Pereira, Enora Laas, Ami Fishman, Caroline C Nitschmann, Katherine Kurnit, Kristen Moriarty, Amy Joehlin-Price, Brittany Lees, Louise De Brot, Cagatay Taskiran, Giorgio Bogani, Fabio Landoni, Luis Chiva, Tommaso Grassi, Tommaso Bianchi, Francesco Multinu, Luigi Antonio De Vitis, Alicia Hernandez-Gutierrez, Spyridon Mastroyannis, Khaled Ghoniem, Emilia Palmieri, Vito Chiantera, Shahi Maryam, Angela J Fought, Michaela E McGree, Andrea Mariani, Gretchen Glaser","doi":"10.1016/j.ijgc.2025.101906","DOIUrl":"10.1016/j.ijgc.2025.101906","url":null,"abstract":"<p><strong>Objective: </strong>This study assessed oncologic outcomes of patients with intermediate-risk endometrioid endometrial cancer and isolated tumor cells (ITC) (≤0.2 mm or ≤200 cells) in sentinel lymph nodes (SLNs).</p><p><strong>Methods: </strong>Patients with SLN-ITC diagnosed between 2012 and 2019 were identified from 19 centers worldwide, while SLN-negative patients were identified at Mayo Clinic, Rochester between 2014 and 2018. Only patients with endometrioid endometrial cancer and intermediate-risk factors (low-grade endometrioid histology and myometrial invasion ≥50%; high-grade endometrioid histology and myometrial invasion <50%) were included. Oncologic outcomes were evaluated by grouping patients according to prognostic factors: SLN-ITC and lymphovascular space invasion (LVSI). SLN-ITC patients with post-operative observation or vaginal brachytherapy (VB) alone were compared with similar node-negative patients.</p><p><strong>Results: </strong>Of the 166 patients included, those with simultaneous presence of SLN-ITC and LVSI were at higher risk of non-vaginal recurrence (HR 3.73 [95% CI 1.17 to 11.84], p = .01) compared with patients who were node-negative with no LVSI. Among the 122 patients (28 SLN-ITC, 94 node-negative) who underwent post-operative observation or VB alone, 1 isolated vaginal recurrence was documented in a node-negative patient, while non-vaginal recurrence occurred in 3 of 28 (10.7%) SLN-ITC and 7 of 94 (7.4%) node-negative patients. The median follow-up was 2.4 years (interquartile range; 1.8-3.0) among the remaining 25 ITC patients and 2.8 years (interquartile range; 0.8-4.2) among the remaining 87 node-negative patients. There was no difference in non-vaginal recurrence-free survival (SLN-ITC: 87.3% [95% CI 74.7% to 100.0%] vs node-negative: 82.2% [95% CI 69.1% to 97.9%], p = .46) or overall survival (SLN-ITC: 76.4% [95% CI 54.3 to 100.0] vs node-negative: 84.5% [95% CI 75.0 to 95.2], p = .28) between the 2 cohorts.</p><p><strong>Conclusions: </strong>In patients with endometrioid endometrial cancer and intermediate-risk factors (including patients who received chemotherapy/external beam radiotherapy), the combination of SLN-ITC and LVSI was associated with worse prognosis compared with patients with no risk factors or only 1 risk factor. In the sub-group of patients who received post-operative observation or VB alone, SLN-ITC did not worsen prognosis relative to node-negative patients.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101906"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mario M Leitao, Kristin L Bixel, Dana Meredith Chase, Allison Quick, Colleen McCormick, Destin Black, Peter C Lim, Ramez N Eskander, Walter H Gotlieb, Salvatore LoCoco, Martin A Martino, Joan L Walker, Larry J Copeland, Bradley J Monk, Leslie M Randall
{"title":"ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer.","authors":"Mario M Leitao, Kristin L Bixel, Dana Meredith Chase, Allison Quick, Colleen McCormick, Destin Black, Peter C Lim, Ramez N Eskander, Walter H Gotlieb, Salvatore LoCoco, Martin A Martino, Joan L Walker, Larry J Copeland, Bradley J Monk, Leslie M Randall","doi":"10.1016/j.ijgc.2025.101760","DOIUrl":"10.1016/j.ijgc.2025.101760","url":null,"abstract":"<p><strong>Background: </strong>The Laparoscopic Approach to Cervical Cancer trial is the only randomized trial to date addressing the role of surgical approach in cervical cancer; however, this non-inferiority trial of minimally invasive surgery vs an open approach in patients undergoing radical hysterectomy for early-stage cervical cancer did not meet its primary end point of 4.5-year disease-free survival and was terminated early because of significantly worse disease-specific survival, overall survival, and locoregional recurrence in the minimally invasive surgery cohort.</p><p><strong>Primary objective: </strong>Our trial compares 3-year disease-free survival after robotic-assisted or abdominal radical or simple (in select cases) hysterectomy in early-stage cervical cancer.</p><p><strong>Study hypothesis: </strong>We hypothesize that disease-free survival is non-inferior after robotic-assisted vs abdominal radical or simple hysterectomy.</p><p><strong>Trial design: </strong>This multi-center, randomized non-inferiority trial conducted through the Gynecologic Oncology Group has specified surgeon qualification criteria. It requires a pelvic magnetic resonance imaging scan in all patients before enrollment and will use 1:1 randomization to assign patients to robotic-assisted or abdominal hysterectomy. All surgeons must use specified tumor-containment techniques in both arms. It does not allow trans-cervical uterine manipulators.</p><p><strong>Major inclusion/exclusion criteria: </strong>Patients with early-stage (2018 International Federation of Gynecology and Obstetrics stages IA2-IB2) cervical cancer. Histologic types are limited to squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. Pelvic magnetic resonance imaging must confirm a tumor that is 4 cm or less without definitive extra-cervical spread. A simple hysterectomy is allowed in select cases after trial study principal investigator review.</p><p><strong>Primary endpoint: </strong>The primary end point is the 3-year disease-free survival between robotic-assisted or abdominal hysterectomy.</p><p><strong>Sample size: </strong>The trial will randomly allocate 840 patients, with planned interim analysis for futility (oncologic safety) after we have randomly allocated 370 and 640 patients.</p><p><strong>Estimated dates for completing accrual and presenting results: </strong>2030.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT04831580.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101760"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and/or fallopian tube cancer: the international HALO study.","authors":"Svetlana Khokhlova, Manwar Abdulelah Alnaqqash, Waleed Bahaj, Salha Bujassoum, Jooyeon Lee, Mohsen Mokhtar, Alexandra Tyulyandina, Carmen Luz Vargas Malaga, Chen-Hsuan Wu","doi":"10.1016/j.ijgc.2025.101645","DOIUrl":"10.1016/j.ijgc.2025.101645","url":null,"abstract":"<p><strong>Objective: </strong>The HALO study (NCT04991051) determined the prevalence of homologous recombination deficiency and its associated factors in patients with high-grade serous/endometrioid ovarian, primary peritoneal, and/or fallopian tube cancers across Asia, the Middle East, and Russia.</p><p><strong>Methods: </strong>This multinational, cross-sectional, real-world study enrolled adult women with newly diagnosed stage III or IV high-grade serous/endometrioid ovarian, primary peritoneal, and/or fallopian tube cancers. Formalin-fixed paraffin-embedded tumor blocks were collected within 120 days of enrollment. The prevalence of homologous recombination deficiency, high genomic instability score (GIS) without tumor BRCA mutations, and BRCA mutations were evaluated along with patient characteristics. Factors associated with homologous recombination deficiency, high GIS without BRCA mutations, and BRCA mutations were identified using a logistic-regression model.</p><p><strong>Results: </strong>Of the 734 patients (median [range] age; 59.0 [23.0-89.0] years), most (92.9%) had a primary ovarian tumor, followed by primary peritoneal (4.1%) and fallopian tube cancers (3.0%). Of the tested 662 patients; 56.0% (371) were homologous recombination deficiency-positive (Asia, 52.0%; the Middle East, 52.2%; Russia, 58.5%). Overall, 204 (30.8%) patients had a high GIS without BRCA mutations (Middle East, 23.9%; Russia, 31.9%; Asia, 41.3%), and 167 (25.2%) had BRCA mutations (Asia, 10.7%; Russia, 26.6%; Middle East, 28.3%). Patients with 1 comorbidity versus no comorbidities (96 vs 207, OR 1.54), a family history of genetically-related cancers versus no family history of cancer (82 vs 224, OR 2.64), and contraceptive use versus no history of contraceptive use (47 vs 323, OR 2.04) were more likely to have homologous recombination deficiency.</p><p><strong>Conclusions: </strong>This real-world study reported a homologous recombination deficiency prevalence of 56.0% (ranging from 52.0% to 58.5%) across Asia, the Middle East, and Russia. Our results highlight the unmet need to implement guideline-recommended testing and real-world data collection for all patients newly diagnosed with advanced high-grade epithelial ovarian cancer to optimize treatment strategies.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101645"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The art of prevention: merging creativity and medicine to transform cervical cancer awareness.","authors":"Gil Zeevi, Ram Eitan","doi":"10.1016/j.ijgc.2025.101909","DOIUrl":"10.1016/j.ijgc.2025.101909","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101909"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Martina Aida Angeles, Esra Bilir, Ilker Kahramanoglu, Helena Obermair, Alexander Shushkevich, Núria Agustí, Aleksandra Strojna, Ana Luzarraga Aznar, David Viveros-Carreño, Nicolò Bizzarri, Andrej Cokan, Houssein El Hajj, Mathilde Del, Elena Rodríguez, Osnat Elyashiv, Stamatios Petousis, Joanna Kacperczyk-Bartnik, Manel Montesinos-Albert, Nadeem Abu-Rustum, Philipp Harter, Isabelle Ray-Coquard, Alejandra Martinez, David Cibula, Henrik Falconer, Rene Pareja, Claudia Marchetti, Murat Gultekin, Frédéric Amant, Mansoor Raza Mirza, Pedro T Ramirez
{"title":"Highlights from the 26th European Congress on Gynaecological Oncology in Rome: interview compilation of the ENYGO-IJGC editorial fellows.","authors":"Martina Aida Angeles, Esra Bilir, Ilker Kahramanoglu, Helena Obermair, Alexander Shushkevich, Núria Agustí, Aleksandra Strojna, Ana Luzarraga Aznar, David Viveros-Carreño, Nicolò Bizzarri, Andrej Cokan, Houssein El Hajj, Mathilde Del, Elena Rodríguez, Osnat Elyashiv, Stamatios Petousis, Joanna Kacperczyk-Bartnik, Manel Montesinos-Albert, Nadeem Abu-Rustum, Philipp Harter, Isabelle Ray-Coquard, Alejandra Martinez, David Cibula, Henrik Falconer, Rene Pareja, Claudia Marchetti, Murat Gultekin, Frédéric Amant, Mansoor Raza Mirza, Pedro T Ramirez","doi":"10.1016/j.ijgc.2025.101913","DOIUrl":"10.1016/j.ijgc.2025.101913","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101913"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Diletta Fumagalli, Aarthi Jayraj, Elena Olearo, Ilaria Capasso, Heng-Cheng Hsu, Yossi Tzur, Sabrina Piedimonte, Bella Jugeli, Beatriz Navarro Santana, Luigi Antonio De Vitis, Giuseppe Caruso, Giovanni Aletti, Nicoletta Colombo, Pedro T Ramirez
{"title":"Erratum to 'Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer' [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101664].","authors":"Diletta Fumagalli, Aarthi Jayraj, Elena Olearo, Ilaria Capasso, Heng-Cheng Hsu, Yossi Tzur, Sabrina Piedimonte, Bella Jugeli, Beatriz Navarro Santana, Luigi Antonio De Vitis, Giuseppe Caruso, Giovanni Aletti, Nicoletta Colombo, Pedro T Ramirez","doi":"10.1016/j.ijgc.2025.101952","DOIUrl":"10.1016/j.ijgc.2025.101952","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101952"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Manohar Pradhan, Wanja Kildal, Ljiljana Vlatkovic, Kari Anne R Tobin, Kristina Lindemann, Gunnar B Kristensen, Andreas Kleppe, Hanne A Askautrud
{"title":"Response to correspondence on prognostic value of tertiary lymphoid structures in molecular subgroups of endometrial carcinoma by Pradhan et al.","authors":"Manohar Pradhan, Wanja Kildal, Ljiljana Vlatkovic, Kari Anne R Tobin, Kristina Lindemann, Gunnar B Kristensen, Andreas Kleppe, Hanne A Askautrud","doi":"10.1016/j.ijgc.2025.101970","DOIUrl":"10.1016/j.ijgc.2025.101970","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101970"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hepatic hilum cytoreductive surgery for ovarian cancer relapse<sup>☆</sup>.","authors":"Myriam Gracia, Constantino Fondevila, Alicia Hernández, Isabel Prieto, María Alonso-Espias, Ignacio Zapardiel","doi":"10.1136/ijgc-2024-005285","DOIUrl":"10.1136/ijgc-2024-005285","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101881"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142286480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}